{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 71 of 128', '11.4 Safety assessments', '11.4.1 Vital signs', 'Vital signs (resting blood pressure, pulse, and body temperature) will be assessed according to', 'the schedule of trial procedures (Section 4). Vital signs will be measured in a supine position', 'following at least 5 minutes of rest.', 'If an abnormal vital sign at screening is considered to be clinically significant by the', 'investigator, it will be at the discretion of the investigator whether the subject should be', 'randomised into the trial (respecting exclusion criterion no. 20).', 'In case of abnormal findings, the vital sign measurement can be repeated approximately', '15 minutes later with the subject resting in a supine position to verify the first measurement.', 'Should the repeated measurement result in a normal value, the measurement must be repeated', 'once more. If the third measurement verifies the second (normal) value, the first measurement', 'should be considered false. If the third measurement confirms the first measurement', '(abnormal), the second measurement will be considered false. Only the last value measured', 'and considered correct will be recorded in the eCRF.', 'Reporting in eCRF', 'Vital signs will be recorded in the eCRF. Clinically significant abnormal vital signs at', 'screening will be documented as medical history in the eCRF. At subsequent visits, any', 'clinically significant deterioration of a pre-existing condition as well as any new clinically', 'significant sign, symptom, or illness will be reported as an AE in accordance with', 'Section 13.3.', '11.4.2 Physical examination', 'A thorough physical examination of the subject including whole body inspection of the skin,', 'auscultation of heart, lungs, and abdomen, palpation of the abdominal organs, and basic', 'neurological status must be performed according to the schedule of trial procedures', '(Section 4). Presence of foot dermatitis will be documented. The investigator should perform', 'the same examinations as in clinical practice as a minimum.', 'If the screening physical examination results in a finding, which is abnormal and of clinical', \"significance, it will be at the investigator's discretion to decide if the subject should be\", 'randomised into the trial (respecting exclusion criterion no. 20).']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 72 of 128', 'Reporting in eCRF', 'It will be recorded in the eCRF if a physical examination was performed and the', 'investigator\\'s evaluation (\\'normal\\', \"abnormal, not clinically significant\\', \\'abnormal,', \"clinically significant'); if a physical examination was not performed, a reason must be given.\", 'Clinically significant abnormal findings at screening will be documented as medical history in', 'the eCRF. At subsequent visits, any clinically significant deterioration of a pre-existing', 'condition as well as any new clinically significant sign, symptom, or illness will be reported', 'as an AE in accordance with Section 13.3.', '11.4.3 ECG', 'A single 12-lead resting digital ECG will be recorded after the subject has been supine for at', 'least 5 minutes at the visits indicated in the schedule of trial procedures (Section 4).', 'A preliminary evaluation of the ECGs will be performed by the investigators to evaluate', 'immediate subject safety. As a minimum, the date of ECG collection will be recorded in the', 'source documents.', 'The ECG data will be transferred to a central ECG service company for central evaluation. A', 'cardiologist at the ECG service company will analyse and interpret the ECG data. The ECG', 'service company will provide ECG evaluation reports to the trial sites.', 'The investigator must evaluate all abnormal ECG results (\\'clinically significant\\' or \"not', \"clinically significant') and sign and date. The investigator has the final decision on the clinical\", 'significance of ECG abnormalities.', 'If the screening ECG results in a finding, which is abnormal and of clinical significance, it', \"will be at the investigator's discretion to decide if the subject should be randomised into the\", 'trial (respecting exclusion criterion no. 20).', 'The collection and transmission of ECG data will be described in a separate ECG manual.', 'Test dummy transmissions will be undertaken prior to trial conduct to ensure that', 'transmissions can be made, and that date and time settings are correctly set.', 'Reporting in eCRF', \"It will be recorded in the eCRF if an ECG was performed and the investigator's assessment of\", \"ECG results ('normal', 'abnormal, not clinically significant', 'abnormal, clinically\", \"significant'); if an ECG was not performed, a reason must be given.\"]\n\n###\n\n", "completion": "END"}